AU2020239026B2 - TYK2 inhibitors and uses thereof - Google Patents

TYK2 inhibitors and uses thereof

Info

Publication number
AU2020239026B2
AU2020239026B2 AU2020239026A AU2020239026A AU2020239026B2 AU 2020239026 B2 AU2020239026 B2 AU 2020239026B2 AU 2020239026 A AU2020239026 A AU 2020239026A AU 2020239026 A AU2020239026 A AU 2020239026A AU 2020239026 B2 AU2020239026 B2 AU 2020239026B2
Authority
AU
Australia
Prior art keywords
cycloalkyl
compound
heterocycloalkyl
independently
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020239026A
Other languages
English (en)
Other versions
AU2020239026A1 (en
Inventor
Qing Dong
Gene Hung
Bohan Jin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alumis Inc
Original Assignee
Alumis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alumis Inc filed Critical Alumis Inc
Publication of AU2020239026A1 publication Critical patent/AU2020239026A1/en
Assigned to ALUMIS INC. reassignment ALUMIS INC. Amend patent request/document other than specification (104) Assignors: ESKER THERAPEUTICS, INC.
Application granted granted Critical
Publication of AU2020239026B2 publication Critical patent/AU2020239026B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2020239026A 2019-03-11 2020-03-10 TYK2 inhibitors and uses thereof Active AU2020239026B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962816698P 2019-03-11 2019-03-11
US62/816,698 2019-03-11
US201962835376P 2019-04-17 2019-04-17
US62/835,376 2019-04-17
US201962877741P 2019-07-23 2019-07-23
US62/877,741 2019-07-23
US201962931119P 2019-11-05 2019-11-05
US62/931,119 2019-11-05
PCT/US2020/021850 WO2020185755A1 (en) 2019-03-11 2020-03-10 Tyk2 inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
AU2020239026A1 AU2020239026A1 (en) 2021-09-23
AU2020239026B2 true AU2020239026B2 (en) 2025-10-09

Family

ID=72427699

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020239026A Active AU2020239026B2 (en) 2019-03-11 2020-03-10 TYK2 inhibitors and uses thereof

Country Status (10)

Country Link
US (2) US20220177486A1 (https=)
EP (1) EP3938369A4 (https=)
JP (1) JP7586829B2 (https=)
KR (1) KR102899985B1 (https=)
CN (1) CN113811534B (https=)
AU (1) AU2020239026B2 (https=)
BR (1) BR112021017996A2 (https=)
CA (1) CA3132632A1 (https=)
IL (1) IL286248B2 (https=)
WO (1) WO2020185755A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019364336B2 (en) 2018-10-22 2023-11-16 Alumis Inc. TYK2 inhibitors and uses thereof
AU2020247990A1 (en) * 2019-03-26 2021-11-11 Ventyx Biosciences, Inc. TYK2 pseudokinase ligands
US12410191B2 (en) 2019-05-21 2025-09-09 Zhejiang Hisun Pharmaceutical Co., Ltd. Macrolide derivatives, preparation method and application thereof
KR102938141B1 (ko) 2019-11-08 2026-03-11 벤틱스 바이오사이언스, 인크. Tyk2 슈도키나제 리간드
AU2021345181A1 (en) * 2020-09-16 2023-05-04 Alumis Inc Tyk2 inhibitors and uses thereof
WO2022117090A1 (zh) * 2020-12-03 2022-06-09 成都科岭源医药技术有限公司 一种多环化合物及其制备方法和用途
JP2024539280A (ja) 2021-10-25 2024-10-28 カイメラ セラピューティクス， インコーポレイテッド Ｔｙｋ２分解剤およびそれらの使用
JP2025509596A (ja) * 2022-03-16 2025-04-11 アルミス インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
WO2023178235A1 (en) * 2022-03-16 2023-09-21 Alumis Inc. Tyk2 inhibitors and uses thereof
WO2023208244A1 (zh) * 2022-04-29 2023-11-02 南京明德新药研发有限公司 大环类化合物及其应用
WO2024199479A1 (zh) * 2023-03-31 2024-10-03 北京普祺医药科技股份有限公司 一种大环化合物、药物组合物及其用途
WO2024222807A1 (en) * 2023-04-27 2024-10-31 Hangzhou Highlightll Pharmaceutical Co., Ltd Novel macrocyclic heteroaryl derivatives as kinase inhibitors
WO2025194074A1 (en) * 2024-03-15 2025-09-18 Neuron23, Inc. Kinase modulators and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010503690A (ja) * 2006-09-18 2010-02-04 ポラリス・グループ タンパク質キナーゼ阻害剤として有用なピラゾロ（１，５−ａ）（１，３，５）トリアジン及びピラゾロ（１，５−ａ）ピリミジン誘導体
WO2017004342A1 (en) * 2015-07-02 2017-01-05 Tp Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
WO2020198379A1 (en) * 2019-03-26 2020-10-01 Ventyx Biosciences, Inc. Tyk2 pseudokinase ligands

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013001310A1 (en) * 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
EP3080131B1 (en) * 2013-12-10 2018-10-10 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
PL3636649T3 (pl) * 2014-01-24 2024-05-06 Turning Point Therapeutics, Inc. Diaryle makrocykliczne jako modulatory kinaz białkowych
US10479793B2 (en) * 2015-11-18 2019-11-19 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
JOP20190092A1 (ar) * 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar) * 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
US11286264B2 (en) * 2017-07-28 2022-03-29 Turning Point Therapeutics, Inc. Macrocyclic compounds and uses thereof
KR102717819B1 (ko) * 2017-07-28 2024-10-14 다케다 야쿠힌 고교 가부시키가이샤 Tyk2 억제제 및 이의 용도
CN109053682B (zh) * 2018-07-27 2020-10-27 东南大学 一种tdo小分子抑制剂衍生物及其抗肿瘤偶联物和制备方法
KR102938141B1 (ko) * 2019-11-08 2026-03-11 벤틱스 바이오사이언스, 인크. Tyk2 슈도키나제 리간드

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010503690A (ja) * 2006-09-18 2010-02-04 ポラリス・グループ タンパク質キナーゼ阻害剤として有用なピラゾロ（１，５−ａ）（１，３，５）トリアジン及びピラゾロ（１，５−ａ）ピリミジン誘導体
WO2017004342A1 (en) * 2015-07-02 2017-01-05 Tp Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
WO2020198379A1 (en) * 2019-03-26 2020-10-01 Ventyx Biosciences, Inc. Tyk2 pseudokinase ligands

Also Published As

Publication number Publication date
WO2020185755A1 (en) 2020-09-17
CA3132632A1 (en) 2020-09-17
KR20210141973A (ko) 2021-11-23
AU2020239026A1 (en) 2021-09-23
IL286248A (en) 2021-10-31
CN113811534B (zh) 2024-10-29
EP3938369A4 (en) 2023-01-25
EP3938369A1 (en) 2022-01-19
BR112021017996A2 (pt) 2021-11-16
JP7586829B2 (ja) 2024-11-19
US20250276977A1 (en) 2025-09-04
CN113811534A (zh) 2021-12-17
IL286248B1 (en) 2025-08-01
US20220177486A1 (en) 2022-06-09
IL286248B2 (en) 2025-12-01
KR102899985B1 (ko) 2025-12-15
JP2022524974A (ja) 2022-05-11

Similar Documents

Publication Publication Date Title
AU2020239026B2 (en) TYK2 inhibitors and uses thereof
JP7631193B2 (ja) Ｔｙｋ２阻害剤およびその使用
CA3192621A1 (en) Tyk2 inhibitors and uses thereof
WO2023178234A1 (en) Tyk2 inhibitors and uses thereof
EP4493562A1 (en) Tyk2 inhibitors and uses thereof
HK40063819B (zh) Tyk2抑制剂和其用途
HK40063819A (en) Tyk2 inhibitors and uses thereof
HK40105557B (zh) Tyk2抑制剂及其用途
HK40105557A (zh) Tyk2抑制剂及其用途
HK40120037A (en) Tyk2 inhibitors and uses thereof
HK40119624A (en) Tyk2 inhibitors and uses thereof
HK40065275A (zh) Tyk2抑制剂和其用途
HK40065275B (zh) Tyk2抑制剂和其用途

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: ALUMIS INC.

Free format text: FORMER NAME(S): ESKER THERAPEUTICS, INC.

FGA Letters patent sealed or granted (standard patent)